Loading...
Loading...
CFRX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 16.0M |
| Operating I/L | -16.0M |
| Other Income/Expense | -4.2M |
| Interest Income | 0.0M |
| Pretax | -20.2M |
| Income Tax Expense | 4.2M |
| Net Income/Loss | -24.3M |
ContraFect Corporation is a clinical-stage biotechnology company focused on developing therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases. The company's lead program, Exebacase, is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. ContraFect also develops CF-296, an engineered lysin, and CF-370, an investigational anti-bacterial therapeutic candidate, targeting staphylococcus aureus and pseudomonas aeruginosa infections. Additionally, the company has initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients.
